RxDoctor Payments Data

Anastasia van Leuven

Surgical · Las Vegas, NVNPI 1851531305

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $5,580 of the $6,380 with a category attached, or 87.5%. It is spread thinly across 32 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,345 and has fallen 60.7% since, to $921 in 2025. Among surgical clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,380in general payments, 2019–2025

Across 300 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Biohaven Pharmaceuticals, Inc.$977
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$813
  • Scilex Pharmaceuticals Inc.$603
  • Forte Bio-pharma LLC$473
  • Pfizer$376
  • plus $2K from 26 others

What the payments were for

  • Consulting fees$80013%
  • Food & beverage$5,58087%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,380 in reported general payments places this provider in the 90th percentile of 91 surgical providers in Nevada.

See all surgical providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen339$61,340
RelistorMethylnaltrexone Bromide15$36,940
OxycontinOxycodone Hcl26$27,638
Xtampza ErOxycodone Myristate31$19,143
Aimovig AutoinjectorErenumab-Aooe25$17,900
MovantikNaloxegol Oxalate36$14,494
Oxycodone Hcl516$13,316
QuliptaAtogepant11$11,312
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen288$8,584
Morphine Sulfate ErMorphine Sulfate304$8,250
ZtlidoLidocaine14$6,338
Diclofenac Sodium35$6,280
Naloxone Hcl71$5,105
Pregabalin170$4,853
Gabapentin296$3,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$813$36,94015 claims
Collegium Pharmaceutical, Inc.Xtampza Er$212$19,14331 claims
Redhill Biopharma Inc.Movantik$93$14,49436 claims
AbbVieQulipta$1,392$11,31211 claims
Scilex Pharmaceuticals Inc.Ztlido$603$6,33814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 91 surgical providers in Nevada.

Other surgical in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →